What is the generic name for Cymbalta (duloxetine)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 3, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Generic Name for Cymbalta

The generic name for Cymbalta is duloxetine. 1

Pharmacological Classification

  • Duloxetine is classified as a selective serotonin and norepinephrine reuptake inhibitor (SNRI) 2, 1
  • It is a balanced and potent inhibitor of both serotonin and noradrenaline (norepinephrine) transporters in the central nervous system 3, 4
  • Duloxetine has weak dopamine transporter inhibition and low affinity for other neuronal receptors including alpha-adrenergic, histamine, muscarinic, and opioid receptors 3

FDA-Approved Indications

Duloxetine is approved for multiple clinical conditions 1:

  • Major depressive disorder (MDD) in adults 1, 4
  • Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years and older 1, 3
  • Diabetic peripheral neuropathic pain (DPNP) 5, 1
  • Fibromyalgia in adults and adolescents 13 years and older 1
  • Chronic musculoskeletal pain, including chronic low back pain and osteoarthritis 2, 1

Standard Dosing

  • The typical starting dose is 30 mg once daily for one week, then increased to 60 mg once daily 2
  • The target maintenance dose for most indications is 60 mg once daily 2, 1
  • The maximum approved dose is 120 mg/day (administered as 60 mg twice daily) 2, 1
  • For diabetic peripheral neuropathy specifically, the FDA-approved dosing range is 60-120 mg daily 5, 1

Key Pharmacokinetic Properties

  • Duloxetine has a mean elimination half-life of approximately 12 hours 3, 6
  • It is extensively metabolized in the liver primarily by CYP1A2 and CYP2D6 enzymes 5, 3
  • Duloxetine is a moderate inhibitor of CYP2D6, which can affect metabolism of other drugs 2, 3
  • Steady-state plasma concentrations are typically reached by day 3 of administration 3

References

Guideline

Duloxetine Scheduling and Clinical Applications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Safety and adverse event profile of duloxetine.

Expert opinion on drug safety, 2005

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.